Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer

Tomoko Yoshihama, Hiroyuki Nomura, Naomi Iwasa, Fumio Kataoka, Shiho Hashimoto, Yoshiko Nanki, Takuro Hirano, Takeshi Makabe, Kensuke Sakai, Wataru Yamagami, Akira Hirasawa, Daisuke Aoki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) is currently one of the preferred treatment options for advanced ovarian, fallopian tube or peritoneal cancer. This study was conducted to evaluate the clinical efficacy and safety of dose-dense paclitaxel plus carboplatin therapy (ddTC therapy) as NAC for these cancers. Patients and methods: A retrospective study was conducted in 25 patients with Stage III/IV ovarian, fallopian tube or peritoneal cancer who received ddTC therapy as NAC. For ddTC therapy, paclitaxel (80 mg/m2) was administered intravenously on Days 1, 8 and 15 and carboplatin (AUC 6.0 mg/ml × min) was administered intravenously on Day 1 every 3 weeks. IDS was performed after three cycles of ddTC therapy, and ddTC therapy was also continued after surgery. Results: With ddTC therapy as NAC, the response rate was 92% and disease progression did not occur in any patient. Grade 4 hematologic toxicity and ≥Grade 3 non-hematologic toxicity both occurred in 8% of the patients, but no patient discontinued NAC because of adverse events. When IDS was performed, the complete surgery rate was 64% and the optimal surgery rate was 96%. ≥Grade 3 perioperative complications occurred in 16% of the patients, but there were no perioperative deaths. Median overall survival was 35.7 months and median progression-free survival was 17.7 months. Conclusion: This study showed that ddTC therapy was considerably effective and tolerable as NAC. The complete surgery rate was high with IDS, and perioperative complications were acceptable.

Original languageEnglish
Pages (from-to)1019-1023
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume47
Issue number11
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Fallopian Tubes
Carboplatin
Paclitaxel
Safety
Drug Therapy
Neoadjuvant Therapy
Neoplasms
Therapeutics
Disease-Free Survival
Area Under Curve
Disease Progression
Retrospective Studies
Survival

Keywords

  • Dose-dense TC
  • Interval debulking surgery
  • Neoadjuvant chemotherapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer. / Yoshihama, Tomoko; Nomura, Hiroyuki; Iwasa, Naomi; Kataoka, Fumio; Hashimoto, Shiho; Nanki, Yoshiko; Hirano, Takuro; Makabe, Takeshi; Sakai, Kensuke; Yamagami, Wataru; Hirasawa, Akira; Aoki, Daisuke.

In: Japanese Journal of Clinical Oncology, Vol. 47, No. 11, 01.01.2017, p. 1019-1023.

Research output: Contribution to journalArticle

Yoshihama, Tomoko ; Nomura, Hiroyuki ; Iwasa, Naomi ; Kataoka, Fumio ; Hashimoto, Shiho ; Nanki, Yoshiko ; Hirano, Takuro ; Makabe, Takeshi ; Sakai, Kensuke ; Yamagami, Wataru ; Hirasawa, Akira ; Aoki, Daisuke. / Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer. In: Japanese Journal of Clinical Oncology. 2017 ; Vol. 47, No. 11. pp. 1019-1023.
@article{23818f73cb7e4ba4a9b9ef671261513b,
title = "Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer",
abstract = "Objective: Interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) is currently one of the preferred treatment options for advanced ovarian, fallopian tube or peritoneal cancer. This study was conducted to evaluate the clinical efficacy and safety of dose-dense paclitaxel plus carboplatin therapy (ddTC therapy) as NAC for these cancers. Patients and methods: A retrospective study was conducted in 25 patients with Stage III/IV ovarian, fallopian tube or peritoneal cancer who received ddTC therapy as NAC. For ddTC therapy, paclitaxel (80 mg/m2) was administered intravenously on Days 1, 8 and 15 and carboplatin (AUC 6.0 mg/ml × min) was administered intravenously on Day 1 every 3 weeks. IDS was performed after three cycles of ddTC therapy, and ddTC therapy was also continued after surgery. Results: With ddTC therapy as NAC, the response rate was 92{\%} and disease progression did not occur in any patient. Grade 4 hematologic toxicity and ≥Grade 3 non-hematologic toxicity both occurred in 8{\%} of the patients, but no patient discontinued NAC because of adverse events. When IDS was performed, the complete surgery rate was 64{\%} and the optimal surgery rate was 96{\%}. ≥Grade 3 perioperative complications occurred in 16{\%} of the patients, but there were no perioperative deaths. Median overall survival was 35.7 months and median progression-free survival was 17.7 months. Conclusion: This study showed that ddTC therapy was considerably effective and tolerable as NAC. The complete surgery rate was high with IDS, and perioperative complications were acceptable.",
keywords = "Dose-dense TC, Interval debulking surgery, Neoadjuvant chemotherapy, Ovarian cancer",
author = "Tomoko Yoshihama and Hiroyuki Nomura and Naomi Iwasa and Fumio Kataoka and Shiho Hashimoto and Yoshiko Nanki and Takuro Hirano and Takeshi Makabe and Kensuke Sakai and Wataru Yamagami and Akira Hirasawa and Daisuke Aoki",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/jjco/hyx118",
language = "English",
volume = "47",
pages = "1019--1023",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer

AU - Yoshihama, Tomoko

AU - Nomura, Hiroyuki

AU - Iwasa, Naomi

AU - Kataoka, Fumio

AU - Hashimoto, Shiho

AU - Nanki, Yoshiko

AU - Hirano, Takuro

AU - Makabe, Takeshi

AU - Sakai, Kensuke

AU - Yamagami, Wataru

AU - Hirasawa, Akira

AU - Aoki, Daisuke

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: Interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) is currently one of the preferred treatment options for advanced ovarian, fallopian tube or peritoneal cancer. This study was conducted to evaluate the clinical efficacy and safety of dose-dense paclitaxel plus carboplatin therapy (ddTC therapy) as NAC for these cancers. Patients and methods: A retrospective study was conducted in 25 patients with Stage III/IV ovarian, fallopian tube or peritoneal cancer who received ddTC therapy as NAC. For ddTC therapy, paclitaxel (80 mg/m2) was administered intravenously on Days 1, 8 and 15 and carboplatin (AUC 6.0 mg/ml × min) was administered intravenously on Day 1 every 3 weeks. IDS was performed after three cycles of ddTC therapy, and ddTC therapy was also continued after surgery. Results: With ddTC therapy as NAC, the response rate was 92% and disease progression did not occur in any patient. Grade 4 hematologic toxicity and ≥Grade 3 non-hematologic toxicity both occurred in 8% of the patients, but no patient discontinued NAC because of adverse events. When IDS was performed, the complete surgery rate was 64% and the optimal surgery rate was 96%. ≥Grade 3 perioperative complications occurred in 16% of the patients, but there were no perioperative deaths. Median overall survival was 35.7 months and median progression-free survival was 17.7 months. Conclusion: This study showed that ddTC therapy was considerably effective and tolerable as NAC. The complete surgery rate was high with IDS, and perioperative complications were acceptable.

AB - Objective: Interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) is currently one of the preferred treatment options for advanced ovarian, fallopian tube or peritoneal cancer. This study was conducted to evaluate the clinical efficacy and safety of dose-dense paclitaxel plus carboplatin therapy (ddTC therapy) as NAC for these cancers. Patients and methods: A retrospective study was conducted in 25 patients with Stage III/IV ovarian, fallopian tube or peritoneal cancer who received ddTC therapy as NAC. For ddTC therapy, paclitaxel (80 mg/m2) was administered intravenously on Days 1, 8 and 15 and carboplatin (AUC 6.0 mg/ml × min) was administered intravenously on Day 1 every 3 weeks. IDS was performed after three cycles of ddTC therapy, and ddTC therapy was also continued after surgery. Results: With ddTC therapy as NAC, the response rate was 92% and disease progression did not occur in any patient. Grade 4 hematologic toxicity and ≥Grade 3 non-hematologic toxicity both occurred in 8% of the patients, but no patient discontinued NAC because of adverse events. When IDS was performed, the complete surgery rate was 64% and the optimal surgery rate was 96%. ≥Grade 3 perioperative complications occurred in 16% of the patients, but there were no perioperative deaths. Median overall survival was 35.7 months and median progression-free survival was 17.7 months. Conclusion: This study showed that ddTC therapy was considerably effective and tolerable as NAC. The complete surgery rate was high with IDS, and perioperative complications were acceptable.

KW - Dose-dense TC

KW - Interval debulking surgery

KW - Neoadjuvant chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85034030388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034030388&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx118

DO - 10.1093/jjco/hyx118

M3 - Article

C2 - 28973541

AN - SCOPUS:85034030388

VL - 47

SP - 1019

EP - 1023

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

ER -